PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
43.89%
Positive growth while VET shows revenue decline. John Neff would investigate competitive advantages.
68.17%
Cost increase while VET reduces costs. John Neff would investigate competitive disadvantage.
30.11%
Positive growth while VET shows decline. John Neff would investigate competitive advantages.
-9.58%
Both companies show margin pressure. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-11.85%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
7262.50%
Other expenses growth while VET reduces costs. John Neff would investigate differences.
-6.82%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
27.29%
Total costs growth while VET reduces costs. John Neff would investigate differences.
9.02%
Interest expense growth above 1.5x VET's 4.73%. Michael Burry would check for over-leverage.
19.00%
D&A growth while VET reduces D&A. John Neff would investigate differences.
5.49%
EBITDA growth while VET declines. John Neff would investigate advantages.
130.06%
EBITDA margin growth while VET declines. John Neff would investigate advantages.
108.64%
Operating income growth while VET declines. John Neff would investigate advantages.
45.00%
Operating margin growth while VET declines. John Neff would investigate advantages.
1768.97%
Other expenses growth above 1.5x VET's 77.63%. Michael Burry would check for concerning trends.
528.07%
Pre-tax income growth while VET declines. John Neff would investigate advantages.
336.49%
Pre-tax margin growth exceeding 1.5x VET's 4.50%. David Dodd would verify competitive advantages.
159.17%
Tax expense growth while VET reduces burden. John Neff would investigate differences.
935.79%
Net income growth while VET declines. John Neff would investigate advantages.
619.84%
Net margin growth exceeding 1.5x VET's 12.29%. David Dodd would verify competitive advantages.
104.86%
EPS growth while VET declines. John Neff would investigate advantages.
104.86%
Diluted EPS change of 104.86% while VET is flat. Bruce Berkowitz would examine quality.
0.01%
Share count reduction exceeding 1.5x VET's 1.13%. David Dodd would verify capital allocation.
0.01%
Diluted share reduction exceeding 1.5x VET's 0.89%. David Dodd would verify capital allocation.